- Amgen adds $300 million to its U.S. manufacturing program, expanding the Juncos, Puerto Rico biologics facility and creating hundreds of construction jobs.
- This follows prior planned investments: $650M in Puerto Rico, $900M in Ohio, $600M for a California science and innovation center, and $1.5B in North Carolina.
- Juncos, established in 1992, is a major biologics site producing medicines distributed to more than 60 countries.
- Amgen reports it has invested over $40 billion in manufacturing and R&D since the 2017 Tax Cuts and Jobs Act, with further support from the 2025 One Big Beautiful Bill Act.
Investment overview
Amgen is investing an additional $300 million in its U.S. manufacturing network to expand biologics production capacity, deploy next‑generation technologies and strengthen medicine supply reliability.
Juncos expansion and jobs
The funding targets expansion of the Juncos, Puerto Rico biologics facility (est. 1992), supporting advanced manufacturing roles, regional workforce development and generating hundreds of construction jobs; the site supplies biologic medicines to more than 60 countries.
Prior investments and policy context
The $300 million builds on earlier announced U.S. investments including $650 million in Puerto Rico, $900 million in Ohio, $600 million for a California science and innovation center, and more than $1.5 billion in North Carolina; Amgen reports it has invested over $40 billion in manufacturing and R&D since the 2017 Tax Cuts and Jobs Act, with further support from the 2025 One Big Beautiful Bill Act.
